Author
Irina Motorina
Bio: Irina Motorina is an academic researcher. The author has contributed to research in topics: Flaviviridae & Flavivirus Infections. The author has an hindex of 2, co-authored 4 publications receiving 109 citations.
Topics: Flaviviridae, Flavivirus Infections
Papers
More filters
Patent•
15 May 2006TL;DR: In this paper, a method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
101 citations
Patent•
15 May 2006TL;DR: In this article, a list of pharmaceutically acceptable salts and solvates for treating flaviviridae viral infections is presented. But none of them are suitable for the treatment of influenza.
Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R 1 , X, Y, Y 1 , and Z are as defined herein, are useful for treating flaviviridae viral infections.
8 citations
Patent•
15 May 2006
TL;DR: Les composes de formule (I) : ou les sels et les solvates de qualite pharmaceutique desdits composes, ou R1, X, Y, Y1 and Z sont tels que definis dans the description of l'invention, peuvent etre employes pour le traitement d'infections virales par un flavivirus.
Abstract: Les composes de formule (I) : ou les sels et les solvates de qualite pharmaceutique desdits composes, ou R1, X, Y, Y1 et Z sont tels que definis dans la description de l'invention, peuvent etre employes pour le traitement d'infections virales par un flavivirus. Ladite infection virale appartient au groupe constitue par le virus de l'hepatite C (VHC), le virus de la diarrhee virale bovine (BVDV), le virus du cholera ovin, le virus de la dengue, le virus de l'encephalite japonaise et le virus de la fievre jaune.
Patent•
15 May 2006
Cited by
More filters
Patent•
07 Feb 2007TL;DR: An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.
Abstract: An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.
379 citations
Patent•
20 Oct 2003TL;DR: In this article, the authors defined a pharmaceutically acceptable salt of the HCV NS3 protease, which is useful as an inhibitor of the NS3 protein-protein interaction.
Abstract: Compounds of formula I: wherein D, R4, R3, L0, L1, L2, R2 and RC are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
269 citations
Patent•
27 Jun 2003TL;DR: Aryl carbonyl derivatives are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokin enzyme activity is beneficial.
Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
144 citations
Patent•
02 Dec 2009
TL;DR: In this article, compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C were presented, including combination therapies and antiviral drugs, for the treatment of the hepatitis C virus.
Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.
126 citations
Patent•
15 May 2006TL;DR: In this paper, a method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
101 citations